ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services (ACCESS)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT06128304 |
|
Recruitment Status :
Recruiting
First Posted : November 13, 2023
Last Update Posted : January 3, 2024
|
Sponsor:
University of California, San Diego
Collaborator:
University of Nigeria Nsukka
Information provided by (Responsible Party):
Gregory Aarons, University of California, San Diego
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
While there has been a significant increase in the uptake of antiretroviral therapy among women living with HIV (WLHIV) in many low- and-middle income countries (LMICs), the coverage of cervical cancer screening and treatment (CCST) among WLHIV remains low. This study aims to leverage the available infrastructure for HIV care and treatment programs in Nigeria to integrate cervical cancer screening and treatment and conduct a cluster randomized, hybrid type III trial design to assess the comparative effectiveness of a Core set of implementation strategies versus a Core+ (enhanced) set of implementation strategies to implement cervical cancer screening, onsite treatment, referral and referral completion, treatment, and retention in care among WLHIV. The overarching goal is to improve the health and life expectancy of WLHIV with co-occurring cervical cancer.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| HIV Cervical Cancer | Other: Core Implementation strategies Other: Core+ Enhanced Implementation Strategies | Not Applicable |
Nigeria has one of the largest HIV epidemics in the world with 1.8 million people living with HIV infection. With an estimated female population of 102 million and HIV prevalence of 1.6% among adult females, Nigeria has the largest population of women and the 4th largest number of women living with HIV (WLHIV) in Africa. Although access to antiretroviral therapy (ART) among WLHIV in Nigeria has increased over the years, with over 98% of the 960,000 WLHIV on ART, AIDS-related mortality remains high. In 2020, 16,000 WLHIV died from AIDS- related illnesses including cervical cancer. A pilot implementation program in Nigeria demonstrated that leveraging the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) supported HIV programs for the provision of evidence-based cervical cancer screen-and-treat interventions in WLHIV is feasible. The pilot program demonstrated, however, that tailored implementation strategies will be needed to address specific multilevel barriers along the cancer control continuum in order to address adoption, reach, and sustainability that are necessary for successful scale-up. However, in many African countries with a high burden of both HIV and cervical cancer, there is a paucity of evidence-based implementation strategies to inform effective integration of HIV and cervical cancer services delivery. Objectives of this proposal are to: 1) Refine strategies to integrate cervical cancer screening, treatment and management within existing comprehensive HIV treatment programs and determine implementation readiness; 2) Determine the comparative effectiveness of a Core set of implementation strategies versus Core+ enhanced implementation strategies; and 3) assess sustainment of the integration of cervical cancer screening, treatment, and management intervention into HIV programs. The investigators have assembled a strong team from University of California San Diego, the University of Nigeria, Nsukka, and Northeastern University with expertise in implementation science, HIV care and research, and cancer care and research. Our proposal is responsive to the NCI request for applications (RFA) and consistent with the World Health Organization global plan of elimination of cervical cancer by 2030. If effective, the proposed project will result in a set of feasible, culturally adaptable, and sustainable implementation strategies to integrate evidence-based cervical cancer screening and treatment into HIV programs in order to improve the health and life expectancy of WLHIV.
| Study Type : | Interventional (Clinical Trial) |
| Estimated Enrollment : | 2436 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Other |
| Official Title: | ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services |
| Actual Study Start Date : | November 13, 2023 |
| Estimated Primary Completion Date : | August 31, 2026 |
| Estimated Study Completion Date : | August 31, 2027 |
Resource links provided by the National Library of Medicine
MedlinePlus related topics:
Cervical Cancer
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Core Implementation Strategies
Core Implementation Strategies
|
Other: Core Implementation strategies
Core Implementation Strategies
Other: Core+ Enhanced Implementation Strategies Includes all of the Core implementation strategies and adds: 5. Community engagement using Health Beginning Initiative Model 6. Smart Cards to facilitate patient engagement |
|
Experimental: Core+ Enhanced Implementation Strategies
Includes all of the Core implementation strategies and adds: 5. Community engagement using Health Beginning Initiative Model 6. Smart Cards to facilitate patient engagement |
Other: Core+ Enhanced Implementation Strategies
Includes all of the Core implementation strategies and adds: 5. Community engagement using Health Beginning Initiative Model 6. Smart Cards to facilitate patient engagement |
Primary Outcome Measures :
- Reach [ Time Frame: 12 months after enrollment ]Percent of WLHIV who had cervical cancer (CC) screening
- Sustainment [ Time Frame: 3 months prior to study completion ]Provider Report of Sustainment Scale (PRESS; Moullin et al., 2021). The PRESS has 3-items scored from 0 "not at all" to 4 "to a very great extent" where higher scores indicate better evidence-based practice sustainment.
Secondary Outcome Measures :
- CCST Effectiveness [ Time Frame: 15 months after treatment of pre-invasive cancer ]Percent of WLHIV treated for pre-invasive cancer who had negative post treatment follow-up screen
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 25 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Gender Based Eligibility: | Yes |
| Gender Eligibility Description: | Female |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Women living with HIV
Exclusion Criteria:
-
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06128304
Contacts
| Contact: Gregory Aarons, PhD | +1 8583350700 | gaarons@health.ucsd.edu | |
| Contact: Echezona Ezeanolue, MD, MPH | +234 803 773 9972 | echezona.ezeanolue@unn.edu.ng |
Locations
| United States, California | |
| UC San Diego | Recruiting |
| La Jolla, California, United States, 92093 | |
| Contact: Joella Phillips, BA 858-966-7703 ext 2695 jiphillips@ucsd.edu | |
| Nigeria | |
| University of Nigeria, Nsukka | Recruiting |
| Enugu, Nigeria | |
| Contact: Echezona Ezeanolue, MD, MPH +1 7024991082 echezona.ezeanolue@unn.edu.ng | |
| Contact: Tonia Onyeka +234 806 356 3223 tonia.onyeka@unn.edu.ng | |
Sponsors and Collaborators
University of California, San Diego
University of Nigeria Nsukka
Investigators
| Principal Investigator: | Gregory Aarons, PhD | University of California, San Diego |
| Responsible Party: | Gregory Aarons, Professor, University of California, San Diego |
| ClinicalTrials.gov Identifier: | NCT06128304 |
| Other Study ID Numbers: |
U01CA275118 ( U.S. NIH Grant/Contract ) |
| First Posted: | November 13, 2023 Key Record Dates |
| Last Update Posted: | January 3, 2024 |
| Last Verified: | December 2023 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | No |
| Studies a U.S. FDA-regulated Drug Product: | No |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by Gregory Aarons, University of California, San Diego:
|
Implementation Science Cluster randomized trial Capacity building Low and middle income countries |
Research infrastructure Exploration Preparation Implementation Sustainment (EPIS) EPIS Framework |
Additional relevant MeSH terms:
|
Uterine Cervical Neoplasms Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Neoplasms Uterine Cervical Diseases |
Uterine Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Diseases |